Lithiofor

Quick links to important sections

Lithiofor

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lithiofor

Property Description
Active Ingredient Lithium Carbonate or Lithium Citrate
Form Tablets (including Extended-Release), Capsules, Oral Solution
Pharmacological Class Mood Stabilizer, Antimanic Agent
General Purpose Stabilizing extreme shifts in mood
Origin Derived from the chemical element, Lithium

What Type of Medicine is Lithiofor?

Lithiofor is a prescription-only medication classified as a Mood Stabilizer and an Antimanic Agent. Its active component is a Lithium Salt, typically Lithium Carbonate. This therapeutic agent is unique because the core component is the Lithium ion, which is derived from a naturally occurring chemical element (alkali-metal group). The overall class is clinically recognized for its efficacy in providing long-term stabilization, particularly for cyclical mood variations. Due to its significance, Lithium Carbonate is considered an essential medicine, confirming its status as a core component of effective health systems worldwide.


Composition and Available Forms

Lithiofor is a single-ingredient product intended for oral administration. The medication is available in several forms, including standard Tablets, Capsules, and specialized Extended-Release Tablets. The development of controlled-release forms is critical because lithium is considered a narrow therapeutic index drug, meaning there is a small difference between the effective concentration and the concentration that can cause adverse effects. Stable blood concentrations are vital for reducing risks associated with this type of therapy. An Oral Solution form is also available, which often utilizes Lithium Citrate.


General Purpose and Mechanism Summary

The general purpose of Lithiofor is to promote fundamental emotional stability and smooth out extreme, cyclical shifts in mood. This stabilizing effect is achieved within the Central Nervous System by influencing multiple biochemical pathways. The high-level mechanism involves altering the transport of ions across nerve cells and modulating the balance of brain messengers (neurotransmitters). This action reduces the overall excitability of nerve tissue, providing the physiological basis for its therapeutic use in helping patients maintain emotional equilibrium.

What side effects are possible with Lithiofor?

Lithiofor’s safety profile is established through official regulatory classifications that organize adverse reactions by frequency and affected body system. Its use is subject to the constraint of its status as a Narrow Therapeutic Index agent, meaning the therapeutic concentration is close to the toxic concentration.

Classification of Adverse Reactions

The adverse effects reported in regulatory documents are classified by frequency, based on official labeling standards:

  • Very Common (Affects 1 in 10 or more): Fine hand tremor, nausea, diarrhea, excessive thirst (polydipsia), frequent urination (polyuria), and weight gain.
  • Common (Affects less than 1 in 10 but more than 1 in 100): Hypothyroidism (underactive thyroid gland), headache, dizziness, ataxia (loss of coordination), and acne.
  • Rare (Affects less than 1 in 1,000): Events such as nephrogenic diabetes insipidus (a severe kidney condition) and specific electrocardiogram (ECG) changes have been documented.

Critical Safety Concerns and Patterns

The most serious concern is Lithium Toxicity (poisoning), which may manifest as confusion, seizures, or irreversible neurological damage if blood levels rise above the therapeutic range. Regulatory documents note that certain common effects like tremor and gastrointestinal upset may be more prominent at the start of treatment or during dose escalation.

Long-term use is associated with potential changes to the thyroid gland and kidney function. Specific safety notes exist for Older Adults and individuals with Renal Impairment due to the increased risk of drug accumulation and toxicity; for those with severe impairment, use is restricted. Maintaining adequate fluid and salt (sodium) balance is critical, as dehydration or sodium loss can rapidly elevate lithium levels and precipitate toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lithiofor toxicity details a progression of clinical manifestations. Early signs may include gastrointestinal symptoms like nausea, vomiting, or diarrhea, alongside neurological findings such as fine tremor, mild ataxia, and drowsiness. Regulators mandate that patients discontinue therapy and contact a physician immediately upon recognizing these initial signs.

Overdose can lead to severe and life-threatening systemic outcomes. These documented complications include neurological sequelae such as seizures and coma, serious cardiovascular events (ECG changes, arrhythmias), and specific conditions like Encephalopathic Syndrome and renal failure. Patients are instructed to seek immediate emergency assistance if they experience severe symptoms like fainting, abnormal heart beats, or shortness of breath.

Management procedures are defined due to the official constraint that no specific antidote is known. For severe toxicity, regulatory information describes procedural measures, including hemodialysis, as the most appropriate means of elimination. The profile also highlights increased risk for specific populations, noting that toxicity is very high in patients with pre-existing renal disease or sodium depletion.

Therapeutic Uses of Lithiofor

What Lithiofor Treats: Main Uses and Benefits

Lithiofor is primarily applied across therapeutic domains involving emotional imbalance and heightened physiological activity. This medication is commonly used to help with conditions characterized by periods of heightened symptoms, such as Bipolar Disorder (to manage both acute manic episodes and to prevent recurrent episodes), and as an augmentation therapy for treatment-resistant Major Depressive Disorder. These applications are relevant across therapeutic areas where additional symptomatic support is needed. It is also relevant for easing pronounced impulsive and aggressive behaviors.

The main benefit contributes to easing the overall symptom load by stabilizing extreme mood changes and helps patients cope more steadily with symptom fluctuations. This support is relevant when supportive symptom management is appropriate.

“The medication is relevant for easing the frequency and intensity of severe episodes, which supports general well-being during symptomatic phases.”

Quick Fact: Relief for Episodic Mood Changes Lithiofor may assist with maintaining functional stability and is considered relevant for sustaining emotional equilibrium during long-term maintenance.

Regulatory References

  1. NIH MedlinePlus Drug Information on Lithium

Eligibility and Restrictions for Use

Eligibility for Lithiofor Use: Official Regulatory Rules

Official regulatory documents define the populations permitted, restricted, or prohibited from using Lithiofor (Lithium Carbonate/Citrate). Eligibility is strictly governed by age, cardiovascular, and renal health due to the drug’s clearance pathway and narrow therapeutic index.

Classification Population/Condition Restriction Basis
Contraindicated Severe renal or cardiovascular disease, Brugada Syndrome, severe dehydration, or sodium depletion (e.g., Addison’s disease) High risk of toxicity
Not Recommended Pregnancy (especially first trimester) Risk of fetal harm, including cardiac anomalies
Not Recommended Children under 7 years of age (standard forms) or under 12 (extended-release forms) Safety and effectiveness not established
Prohibited Patients who are breastfeeding Excretion into human milk

Use is restricted and requires extreme caution in the Geriatric Population and patients with mild-to-moderate renal impairment or those concurrently receiving diuretics, as these groups face a heightened risk of lithium toxicity. Additionally, conditions that cause fluid loss, such as fever or diarrhea, require a temporary reduction or cessation of the medicine, as documented in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lithiofor's interaction profile is significantly influenced by medicines that alter renal function, fluid balance, or have concurrent effects on the central nervous system. The official regulatory documents require close monitoring whenever a patient is concurrently taking specific classes of medicines.

Exposure-Altering Co-administered Medicines

Interacting Product Category Mechanism and Constraint
Diuretics (Thiazides, Loop, etc.), NSAIDs, RAS Antagonists (ACE inhibitors) These drugs can decrease lithium excretion, potentially leading to increased serum lithium concentrations and toxicity. Monitoring of lithium levels must be intensified upon initiation or dosage change.
Metronidazole, Tetracyclines Co-administration may result in increased lithium serum concentrations, necessitating frequent monitoring and possible dose adjustment.
SGLT2 Inhibitors (e.g., Dapagliflozin, Empagliflozin) These medicines may decrease serum lithium concentrations, requiring more frequent monitoring to maintain effectiveness.
Acetazolamide This drug may increase the rate of lithium excretion, potentially decreasing lithium serum concentration.

Pharmacodynamic Synergistic Risks

Concomitant use with Serotonergic Agents (including SSRIs and triptans) may increase the risk of Serotonin Syndrome. Use with Antipsychotics has been linked to reports of neurological adverse reactions. Maintaining adequate salt and fluid intake is essential, as dehydration or changes in sodium intake can alter lithium levels and increase the risk of toxicity.

The regulatory structure for this product demands routine and intensified monitoring of serum lithium concentrations when introducing any known interacting medicine to ensure safety and maintenance of stable exposure.

Mechanism of Action

Molecular Basis: Signal Dampening via Enzyme Inhibition

This mechanistic domain covers the action of Lithiofor as a non-competitive inhibitor of key intracellular enzymes, primarily Inositol Monophosphatase (IMPase) and Glycogen Synthase Kinase-3 (GSK-3) beta within neural tissue. Inhibition of IMPase disrupts the phosphatidylinositol (PI) signaling cascade, leading to the dampening of intracellular signal amplification and influencing the propagation of excitatory signals.


Influence on Neuroplasticity and Cellular Pathways

Inhibition of GSK-3 beta extends beyond acute signaling by modulating cellular survival pathways. This mechanism influences the expression of specific transcription factors, contributing to the upregulation of neurotrophic factors like Brain-Derived Neurotrophic Factor (BDNF), which influences the long-term structural organization and plasticity of neural circuits.


Modulation of Excitatory and Inhibitory Neurotransmission

Lithiofor further influences central nervous system signaling by enhancing inhibitory GABAergic activity while simultaneously attenuating excitatory glutamate and dopamine pathways. This multiple-system modulation influences the overall electrochemical balance and alters the characteristic signaling patterns within the central nervous system.

Dosage and Administration Information

How to Use Lithiofor

Lithiofor, which contains a lithium salt, is a prescription medicine intended strictly for oral administration. The usage pattern is specifically structured around maintaining stable concentrations of the lithium ion in the blood. This requires consistent adherence to a highly specific dosing regimen.


Administration Principles and Scheduling

Administration is typically done in divided doses two or three times daily for immediate-release forms to promote concentration stability. For maintenance, a once-daily schedule is sometimes employed, especially when using extended-release formulations. It is essential to take the dose(s) at the same time(s) each day. All extended-release tablets must be swallowed whole; they must not be crushed, chewed, or divided.

To help mitigate gastrointestinal effects, the medication is usually taken with food. Patients are also directed to maintain both a normal salt diet and an adequate daily fluid intake (e.g., 2500 to 3000 mL) to prevent fluctuations that could affect the drug's predictable behavior in the body.

Dosing and Monitoring Protocol

The dosage is not fixed and follows a principle of titration, beginning with a low starting dose (e.g., 600 mg two to three times daily for acute use) and gradually adjusting upwards. The highest recommended total daily dose for adults typically ranges from 1200 mg to 1800 mg during acute stabilization. Due to the drug's narrow therapeutic index, dosage adjustments are guided by regular measurement of serum lithium concentration in blood samples drawn 8 to 12 hours after the last dose. Dosage reduction is generally required for older adults and individuals with renal impairment. If treatment is to be stopped, the dose should be reduced gradually over weeks or months.

Recent Clinical Evidence

Lithiofor: Recent Clinical Evidence

This section summarizes the official structure of the clinical research conducted on Lithiofor's active component (Lithium Salt), detailing the study types performed, the outcomes that were measured, and the limitations noted by researchers.


Evidence Structure by Condition

The research for conditions characterized by fluctuating manifestations, such as Bipolar Disorder, includes an extensive collection of Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily monitored outcomes related to manic symptom severity and tracked the frequency of episode recurrence for manic, depressive, and mixed episodes.

For Treatment-Resistant Depression, RCTs designed as augmentation studies have explored outcomes related to response rate and changes in depressive symptom scores when the component was added to existing therapy. Separately, controlled trials have also been conducted to monitor changes in impulsive and aggressive behavior scores in specialized populations.


Long-term Data and Research Gaps

Research has explored various time intervals to understand the component’s patterns of action, including long-term data that monitored patients over extended time intervals for maintenance outcomes. However, the evidence does not fully characterize certain long-term intervention dynamics for all uses, particularly in specialized areas like augmentation.

Evidence remains limited for specific subgroups, such as pregnant populations or those with complex comorbidities. Additionally, comparative evidence is lacking, as there is a relative scarcity of recent, direct trials comparing this component to many newer therapeutic options. Findings describe group patterns, and research provides context but not individual predictions.

Key Studies & References

  1. Lithium: Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Lithiofor (FAQ)


Q: How quickly should I expect to feel the effects of Lithiofor?

A: Studies and official information indicate that it may take several weeks for the full, intended therapeutic effects of Lithiofor to become stable. During the initial phase, serum drug concentrations are often monitored to determine the optimal level for stabilization.


Q: Can I drink alcohol in moderation while on Lithiofor?

A: Regulatory information advises limiting or avoiding alcohol. This is because alcohol can increase central nervous system side effects such as drowsiness, dizziness, and difficulty concentrating. Patients are cautioned about activities requiring full alertness due to this risk.


Q: Can Lithiofor be used safely during pregnancy?

A: The drug is generally not recommended for use during the first three months of pregnancy due to a small potential risk of cardiac malformations in the baby. If pregnancy is planned or occurs while taking Lithiofor, regulatory documents recommend that the treatment plan be reviewed by a qualified specialist.


Q: What happens if I miss a dose of Lithiofor?

A: If a dose is forgotten, it is important not to double the next dose to compensate. Official prescribing information states that missed doses should be discussed with a healthcare provider for specific guidance on management.


Q: Can Lithiofor cause hair loss?

A: Yes, hair loss, medically known as alopecia, is listed as a possible dermatologic side effect associated with the use of this medication in regulatory documents.


Q: Will Lithiofor affect my sleep patterns?

A: Drowsiness (somnolence) and lethargy are documented neurological adverse reactions to Lithiofor. If these effects occur, they may affect sleep-wake patterns, although side effects often improve after the first one to two weeks of treatment.


Q: What should I do if I experience nausea from Lithiofor?

A: Nausea is listed as a very common side effect, especially during the initial days of use. Taking the medication with food may help reduce gastrointestinal discomfort, according to official administration guidelines.


Q: Is it necessary to inform my dentist or surgeon that I'm on Lithiofor?

A: Regulatory documents recommend informing all healthcare professionals, including surgeons and dentists, about the use of this medicine. Conditions like dehydration and changes to electrolyte balance during procedures can increase the risk of toxicity.


Q: Can Lithiofor make you feel tired or drowsy?

A: Yes, official regulatory labeling lists drowsiness (somnolence) and lethargy as documented adverse effects of Lithiofor. Patients should be aware of this potential side effect when engaging in activities that require full attention.


Q: Is it normal to have increased thirst when starting Lithiofor?

A: Yes, official product information lists excessive thirst (polydipsia) as a very common side effect. This may occur during the initial phase of treatment and can persist, requiring consistent fluid intake.


Q: Is Lithiofor the same as regular lithium, or is it different?

A: Lithiofor contains the active component lithium salt, which is the same core element used in other forms of lithium treatment. The different formulations, such as extended-release tablets, are designed to affect how the lithium ion is absorbed and maintained in the body.


Q: How long does Lithiofor stay in your system?

A: According to pharmacokinetics data, the elimination half-life of lithium is approximately 24 hours. This means it takes about one day for half the drug to be eliminated from the body, though the therapeutic benefits may persist.


Q: Is Lithiofor effective for anxiety or just mood swings?

A: The drug is officially indicated for the treatment of manic episodes associated with Bipolar Disorder and for maintenance to help prevent episode recurrence (mood swings). Official labeling does not list anxiety as an approved indication for this medication.


Q: Can Lithiofor be taken with common supplements like vitamins or herbal remedies?

A: Official information generally advises caution before taking any other products, including vitamins, herbal remedies, or supplements. This is because these substances may interact with Lithiofor or affect its action, and should be discussed with a healthcare provider.


Q: Are there possible long-term side effects of Lithiofor treatment?

A: Regulatory warnings note that long-term treatment is associated with the potential for changes in thyroid gland function, such as hypothyroidism, and changes in kidney function, including a decreased ability to concentrate urine.


Q: Can taking Lithiofor affect my ability to drive or operate machinery?

A: Since the medication can cause side effects like drowsiness, dizziness, and motor incoordination, patients are cautioned to avoid driving or operating hazardous machinery until they understand the drug's effect on their alertness and motor skills.


Q: Are there withdrawal symptoms if I stop taking Lithiofor suddenly?

A: Regulatory documents state that the medication is generally discontinued gradually over weeks or months to help reduce the risk of symptom relapse. Abrupt discontinuation is not recommended.


Q: Does Lithiofor need to be taken with food?

A: Official administration instructions indicate the medication is usually taken with food. This practice helps to reduce the potential for stomach upset and irritation.


Q: Can Lithiofor be crushed or split if swallowing is difficult?

A: Extended-release tablets must be swallowed whole and should not be crushed, chewed, or divided. This is because altering the form can lead to uncontrolled release and an increased risk of toxicity, according to official labeling.


Q: Does Lithiofor interact with caffeine intake?

A: Caffeine may reduce the level of the medication in the blood, which could potentially decrease its effectiveness. Patients are advised to maintain consistent consumption levels of caffeine and to discuss any significant changes in intake with their healthcare provider.


Q: Are there any known severe or rare side effects of Lithiofor I should watch out for?

A: Yes, regulatory documents list several severe effects, including lithium toxicity, which requires immediate medical attention. Rare but serious effects like nephrogenic diabetes insipidus (a severe kidney condition) and specific cardiac abnormalities have also been documented.


Q: How long does it take to stabilize on a dose of Lithiofor?

A: The process of stabilization involves careful monitoring. Regulatory protocol requires that serum lithium concentrations be measured frequently (typically twice weekly) during the initial treatment phase until the drug level and the patient's clinical condition have been stabilized.


Q: Is it normal to feel a metallic taste after taking Lithiofor?

A: Yes, a metallic taste, which is a form of taste distortion medically termed dysgeusia, is listed as a possible adverse reaction to the medication.


Q: Can Lithiofor affect blood sugar levels?

A: Regulatory documents report that the drug has been associated with transient hyperglycemia, which means a temporary elevation of blood sugar, as a possible adverse reaction.


Q: Can Lithiofor affect the concentration of salt in my body?

A: Official warnings stress that a low salt intake or excessive loss of fluids and salt (sodium) from the body can cause the drug to accumulate and lead to toxicity. Maintaining a normal salt intake is necessary while taking this medicine.


Q: How does a doctor decide the right starting dose of Lithiofor?

A: Dosage is not fixed and must be personalized based on the patient's clinical response and confirmed by regular measurements of their serum lithium levels. Official labeling notes that lower initial doses may be required for older adults or individuals with impaired kidney function.


Q: Is Lithiofor a controlled substance?

A: No, the drug is officially classified as an antimanic agent and mood stabilizer for therapeutic use and is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

How should Lithiofor be stored and disposed of?

How to Store and Dispose of Lithiofor

Official regulatory labeling dictates specific storage and disposal requirements for lithium carbonate to maintain product stability and patient safety.

Storage Requirements

Lithiofor must be stored at Controlled Room Temperature, generally defined as 20 C to 25 C (68 F to 77 F), with protection from both excessive heat and moisture. The product must be kept in its original container and maintained tightly closed to protect it from light. It is a mandatory safety instruction to Keep out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired medication must follow official health authority guidance. The preferred method is using a drug take-back program. If no program is available, the product must be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. All personal identifying information must be removed from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lithiofor found in:

A-Z Index: